Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03396211 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Apatinib (Also Known as Rivoceranib) Plus Nivolumab in Participants With Unresectable or Metastatic Cancer
A Phase 1 study, sponsored by Elevar Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT03396211 is a Phase 1 study that has completed, run by Elevar Therapeutics. The registered enrollment target is 30 participants.
The verdict
NCT03396211, a Phase 1 study, has completed, sponsored by Elevar Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is an open-labeled, single-center, Phase I study to evaluate the safety, tolerability, and efficacy of apatinib with nivolumab treatment in participants with unresectable or metastatic cancer. Total study duration will be approximately 50 months: 12 months of recruitment plus 6 months of treatment and subsequent survival follow up.
Interventions
- DRUG Nivolumab
- DRUG Apatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2017-12-22 |
| Est. Completion | 2022-03-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03396211
The ClinicalTrials.gov registry entry for NCT03396211 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Elevar Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT03396211 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03396211 about?
NCT03396211 is a clinical study titled "A Study to Evaluate Apatinib (Also Known as Rivoceranib) Plus Nivolumab in Participants With Unresectable or Metastatic Cancer". This is an open-labeled, single-center, Phase I study to evaluate the safety, tolerability, and efficacy of apatinib with nivolumab treatment in participants with unresectable or metastatic cancer. Total study duration will be approximately 50 months: 12 months of recruitment plus 6 months of treatm...
What is the current status of trial NCT03396211?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2017-12-22. Estimated completion is 2022-03-16.
What interventions are being tested in trial NCT03396211?
The interventions under investigation include: Nivolumab (DRUG), Apatinib (DRUG).
Who is sponsoring clinical trial NCT03396211?
This trial is sponsored by Elevar Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.